Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Does anyone know if Biogen might possibly be the manufacturer for Anavex 2-73?
Manufacturing not mentioned in the Biogen/Eisai PR, but it was mentioned in the last one.
If the drug works
Look for Biogen to make a sweet offer of billions
Which I believe will be accepted
Now that will be for Alzheimer’s
Let’s see how the rest of the game unfolds in the next few years
Not For Sale Now. Never For Sale to BIIB.
You can’t take out the poor Responders data out of one group and leave it all the others and then say this group responded better..
What the hell.. called FRAUD
AVXL is not for sale.
IF BIIB buys AVXL I think BIIB goes quickly to $500/share. Best results in Alzheimers I have seen and will be huge in all CNS diseases.
And ....
As long as Biogen continues to make a lot of money
The opportunities for Anavex to get a big payday from them remains on the table
So go Biogen
Keep making a lot of money
The small print says there could
Be some brain swelling in up to 10% of the population
That’s not what the FDA will look too kindly at
And it won’t be he first time a
Major bio company gets a late stage drug denied approval and the we all know what happens to the share price then
Wait and see
Yes, Biogen acting like a penny pump.
Is Biogen cheating = act dishonestly or unfairly in order to gain an advantage? http://blogs.sciencemag.org/pipeline/archives/2018/07/06/biogen-and-eisai-tease-an-alzheimers-result
Next stage of national drug trial underway
By Sandy Cheu on July 13, 2018 in Industry, Research & Clinical
FacebookTwitterGoogle+LinkedInEmailMore
Dementia specialist aged care provider HammondCare is leading the Australian component of an international trial testing a drug that aims to slow down cognitive decline in people with Alzheimer’s disease.
The trial is recruiting 450 people aged 60-85 living with mild cognitive impairment or mild Alzheimer’s disease across 12 sites nationally and will run for a minimum of 12 months.
It aims to demonstrate that the drug Anavex 2-73 shows benefits and improvements to those living with Alzheimer’s disease and to bring the drug to the market in the future.
The drug is a disease-modifying therapy and this trial follows promising results in an earlier Australian study, which achieved significant cognitive improvement in some participants.
This trial will test whether the drug can stabilise the progression of the disease, said Associate Professor Stephen Macfarlane, head of clinical services at HammondCare and principal investigator of the trial.
Professor Stephen Macfarlane
“It’s also important if we can slow the rate of cognitive decline to a meaningful degree,” Associate Professor Macfarlane told Australian Ageing Agenda.
“Improvement is asking a lot from a brain that is significantly damaged by the time people first develop symptoms,” Professor Macfarlane said.
While the causes of Alzheimer’s disease are unknown, damage to the brain from a build-up of toxin proteins is a theory, Professor Macfarlane said.
“We really need a drug that can impact on the course of the disease, not only to save lives but also save on future aged care costs,” Professor Macfarlane said.
“If the trial itself is successful and we come across a drug that modifies the course of the disease, it would be a complete game changer as far as aged care requirements go,” he said.
Previous findings
The trials are being run by American biopharmaceutical company Anavex Life Services and involved laboratory and animal testing in the first phase.
In Australia, the second phase of the trial, which commenced in 2015, involved 32 people with mild Alzheimer’s disease over a 12-month period across five sites in Melbourne.
A company sponsoring the new trial is working to determine the characteristics that differentiated participants who responded well to the drug compared to those who responded less well through genetic analysis and dosage amounts, Professor Macfarlane said.
“The new trial is designed to leverage those learnings from the earlier study and try to maximise the chances for success,” he said.
For many participants of the previous trial, their results at 12 months showed their cognitive status remained largely unchanged, he said.
Professor Macfarlane said some participants also regained functions previously lost, such as the ability to paint and play the piano while a person who re-sat the driving exam successfully regained their licence.
At the end of the study, participants requested an extension to continue to have access to the drug, which was granted.
In addition to this trial, Anavex received approval to earlier this week to also commence trialling the drug with people living with Parkinson’s disease and dementia.
https://www.australianageingagenda.com.au/2018/07/13/next-stage-of-national-drug-trial-underway/
Comment below to have your say on this story
Send us your news and tip-offs to editorial@australianageingagenda.com.au
Subscribe to Australian Ageing Agenda magazine and sign up to the AAA newsletter
LOL! Can you imagine the uproar if Anavex created a "novel measure of efficacy"?
IMO BIIB starts to fill the gap up tomorrow.
Anavex up - Biogen down.
Biogen and Eisai stacked the deck:
The drug, BAN240, failed before. So what's new. Biogen and Eisai stacked the deck, that's what's new.
WSJ article: ”Analysts said questions remain about the results of the BAN2401 study. For one thing, researchers used a novel measure of efficacy that was developed by Eisai’s in-house researchers, rather than standard measures in the field.”
They, the foxes in the henhouse, arranged things for a desired outcome by internally coming up with a new measure of efficacy. Biogen’s partner Eisai, a Japanese pharmaceutical company, came up with a new standard to measure ”success”. Even then this ”success” is not so great considering their drug is an infusion and the same WSJ article points out: ”The study involved 856 subjects in the early stage of the disease. Among the side effects that the companies reported were reactions at the sites of the infusion and swelling around blood vessels observed with brain imaging.” Making multiple trips to a clinic or medical office for infusions as opposed to taking a pill poses difficulties in addition to the risks of adverse events, and for what: BAN240 does not stop or reverse Alzheimer’s.
I though that this won't move that much. Should pull a trigger and buy this, instead bought something else and lost money there. Oh well, can't win them all.
Xena I think you are on point the pump before the dump, miles behind Anavex, just a rehash of a phase 2 study.
Biogen institutional ownership 88.9% -
This could be the pump where the rats start to leave a sinking ship. There is no way I would call that study "positive". IMO it will never go to P3.
https://www.nasdaq.com/symbol/biib/institutional-holdings
Day trade, play the momo, going to 360+ on huge vol.
yes..again..calling intraveneous dosing 18 months in a success because of the SLOWING of the DECLINE..sounding a lot like AXON or DPZ..
I think VTVT had a better results than this with low plasma level daily pill..I don't want ot be negative about Biogen..I own and believe another company has a better solution..Anavex..
Maybe this drug as an adjunct to Anavex's a2-73..Injections are just
NOT the solution to alzheimers crisis..unless of course they stop and/or reverse..
Biogen has cried wolf ..before..
To expensive to buy this. Not worth it.
"successfully demonstrating potential "
Full on equivocation mode ....
We are talking P2 here folks.
This is an IV infusion - cumbersome administration.
Does anyone have a comparison of "slower progression" of Donepezil as compared to BAN 2401?
Much ado about nothing, IMO.
https://clinicaltrials.gov/ct2/show/NCT01767311
Yeah, but today's pump PR isn't going to cut it. After all that drama we have this:
The current ALZ trial that BIIB is hoping for a win with has less than 150 patients. I hope they do get a win for that terrible disease. they have nice sales but as analysts have stated a very thin pipeline. they could buy some companies though to fill the void.
I did not just started watching it. I posted before the two ALZ failures were PR later. So maybe BIIB is up on the other two ALZ drug failures. Problem with taking bear position on puts is they have so many other drugs and will not get a readout on ALZ trial for a long time. What would worry me most for BIIB value is if Dems get control in House of Congress next year and haul BIIB before a subcommittee and spear them for raising drug prices 2x the normal yearly gouge. They got away with it so far.
Hope you didn’t do that yesterday. Up 15 today. I might buy some puts.
Apparently the market agrees with my analysis at least as of 10 am 31st day of earnings1.25.2018. Good earning but essentially zero to help pipeline. It seems the acquisition talks by management was just smoke screen.. Looks like could develove into a full blown train wreck. Shorting with naked puts might be a trade here.
BIIB up premarket on earnings report but I think the whole market might actually be disappointed that so little is being done to bolster BioGen's decaying pipeline.
BioGen at least seems to have been able to steeply increase the price of its MS legacy drugs but that does not figure to be a sustainable strategy and really smoke and mirrors because the real price is negotiated with the Insurance Cos., Medicaid/care and Pharmacy benefit management.
The market might see the paltry acquisition today as dangerous complacency of BioGen management with the state of its pipeline.
AVXL: Getting some pin action from BIIB's news today.... Volume and price increasing...
Oops, was referring to today’s news.
That SUCKs, I just had some dinner with some BioGen risk management execs over the weekend and everyone was hoping for success even tough the odds were not good.
It certainly isn’t over though, they will keep trying.
I can’t speak for anyone else
However since we have seen zilch from Biogen regarding anavex
The best bet is to assume it’s just not there
Best of luck
That post was put out there as a farce
Sorry if you misunderstood
Absolutely not
And my opinion is
Not there
Wait for other stuff to unfold
Wow
Any clue where these rumors are coming from other than posters on this board?
Biogen getting very aggressive about protecting their MS market -
Hoping for some new revelations soon..
amyloid/A.D.
Does anyone know or have an estimate of when phase 3 will be wrapped up?
In the meantime, would they allow for "expanded access"/compassionate use while it is in clinical trial?
Yes, unsubstantiated indeed. Believe it when I see it!
29 billion?!
Now that's new
Unsubstantiated rumor going around that Biogen is buying anavex for 29 billion
Biogen Inc. raises forecast on beating second quarter revenue estimates. TECFIDERA, Biosimilars shine.Earnings Infographic
Followers
|
43
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
628
|
Created
|
11/17/07
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=BIIB
Biogen Idec Inc., a biotechnology company, develops, manufactures, and commercializes novel therapeutics in the areas of neurology, oncology, immunology, cardiopulmonary, and hemophilia in the United States and internationally. The company?s marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, low-grade or follicular, CD20-positive, and B-cell Non-Hodgkin?s Lymphoma (NHL); TYSABRI to treat relapsing MS; and FUMADERM for the treatment of severe psoriasis. Its products under development consist of BG-12, a Phase III clinical trial product for the treatment of MS; Humanized Anti-CD20 MAb, a Phase III clinical trial product for the treatment of rheumatoid arthritis and lupus nephritis; Lixivaptan, a Phase III clinical drug for the treatment of Hyponatremia; Daclizumab, a Phase II monoclonal antibody that is being tested in relapsing MS; and Fampridine, an oral compound as a treatment to improve walking ability in people with MS. The company?s products under preclinical stage comprise BIIB014, Ocrelizumab, Neublastin, LINGO, and BART for neurology; Hsp90 Inhibitor, GA101, Anti-IGF-1R, Volociximab, Anti-CRIPTO, RAF Inhibitor, and Anti-Fn14 for oncology; Anti-TWEAK, Anti-CD40L Fab, and Anti-FcRn for immunology; and Long-acting rFactor VIII for hemophilia. It has collaboration agreements with Neurimmune SubOne AG; Cardiokine Biopharma LLC; UCB, S.A.; Swedish Orphan Biovitrum AB; Facet Biotech Corporation; Vernalis plc; and Schering AG. The company was founded in 1985 and is based in Cambridge, Massachusetts.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |